Pharmacogenomics Advances: Customizing Drug Therapies for Individual Patients


  • Priya Singh Student, Department of pharmaceutical Science & Technology, AKS University, Satna.


Pharmacogenomics, Precision Medicine, Genetic Variations, Drug Metabolism, Personalized Medicine, Clinical Applications, Technological Advancements, Challenges, Ethical Considerations, Future Prospect


By adapting medication therapy to a patient’s genetic profile, the emerging science of pharmacogenomics, which combines genetics with pharmacology, promises to transform medical practice. The fundamental ideas of pharmacogenomics are clarified in this review paper, which also emphasizes how genetic variants affect how drugs work. Technological advancements in bioinformatics and high-throughput sequencing have enabled thorough genetic investigations, enabling the identification of critical variations connected to pharmacological effects. Clinical applications are found in many different medical specialties, such as oncology and psychiatry, where genetic knowledge improves treatment options and results. However, issues with diverse databases, variation interpretation, ethical issues need to be addressed. Looking ahead, the advancement of point-of-care genetic testing and the merging of pharmacogenomic data with other omics information both offer enormous potential. A  \ comprehensive strategy to deal with these issues will be crucial in realizing pharmacogenomics’ revolutionary effects as it moves closer to being a standard part of medical care.


Evans, W. E., & Johnson, J. A. (2013). Pharmacogenomics: The inherited basis for interindividual differences in

drug response. Annual Review of Genomics and Human Genetics, 14, 115-138.

Relling, M. V., & Klein, T. E. (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics, 89(3), 464-467.

Swen, J. J., Wilting, I., de Goede, A. L., Grandia, L., Mulder, H., Touw, D. J., ... & Guchelaar, H. J. (2008). Pharmacogenetics: from bench to byte—an update of guidelines. Clinical Pharmacology & Therapeutics, 83(5), 781-787.

Crews, K. R., & Relling, M. V. (2011). Clinical pharmacokinetics and pharmacodynamics and pharmacogenomics of therapeutic monoclonal antibodies used for cancer therapy. Clinical Pharmacokinetics, 50(10), 661-680.

Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alfoldi, J., Wang, Q., ... & Consortium, G. P. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 581(7809), 434-443.

Haga, S. B., Burke, W., Ginsburg, G. S., Mills, R., & Agans, R. (2021). Primary care physicians’ knowledge, attitudes, experience with pharmacogenetic testing. Clinical Genetics, 99(3), 416-425.

Lee, J. W., Aminkeng, F., Bhavsar, A. P., Shaw, K., Carleton, B. C., Hayden, M. R., & Ross, C. J. (2016). The emerging era of pharmacogenomics: current successes, future potential, challenges. Clinical Genetics, 89(3), 283-291.

Caudle, K. E., Klein, T. E., Hoffman, J. M., Müller, D. J., Whirl-Carrillo, M., Gong, L., ... & Relling, M. V. (2014). Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Current Drug Metabolism, 15(2), 209-217.

Shuldiner, A. R., O’Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., Horenstein, R. B., ... & Chew, D. P. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 302(8), 849-857.

Gottesman, O., Scott, S. A., Ellis, S. B., Overby, C. L., Ludtke, A., Hulot, J. S., ... & Glaser, N. S. (2013). The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clinical Pharmacology & Therapeutics, 94(2), 214-217.

Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., ... & Haidar, C. E. (2015). Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annual Review of Pharmacology and Toxicology, 55, 89-106.

Yang, J. J., Cheng, C., Devidas, M., Cao, X., Campana, D., Yang, W., ... & Winter, S. (2015). Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood, 126(6), 757-763.

Relling, M. V. (2004). Pharmacogenetics of cancer therapy: getting personal. Journal of Clinical Oncology, 22(15), 3655-3656.

Caudle, K. E., Dunnenberger, H. M., Freimuth, R. R., Peterson, J. F., Burlison, J. D., Whirl-Carrillo, M., ... & Hoffman, J. M. (2017). Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation

Consortium (CPIC). Genetics in Medicine, 19(2), 215- 223.

Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W., ... & Weinshilboum, R. M. (2018). Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clinical Pharmacology & Therapeutics, 93(4), 324-325.

Relling, M. V., & Klein, T. E. (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics, 89(3), 464-467.

Caudle, K. E., Sangkuhl, K., Whirl-Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., ... & Gaedigk, A. (2017). Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical Chemistry, 63(12), 1555-1568.

Kitzmiller, J. P., Groen, D. K., Phelps, M. A., & Sadee, W. (2016). Pharmacogenomic testing: relevance inmedical practice: why drugs work in some patients but not in others. Cleveland Clinic Journal of Medicine, 83(11), 892-899.

Relling, M. V., Schwab, M., Whirl-Carrillo, M., Suarez- Kurtz, G., Pui, C. H., Stein, C. M., ... & Klein, T. E. (2020). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy. Clinical Pharmacology & Therapeutics,

(4), 865-874.

Van Driest, S. L., Shi, Y., Bowton, E. A., Schildcrout, J. S., Peterson, J. F., Pulley, J. M., ... & Roden, D. M. (2014). Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clinical Pharmacology & Therapeutics, 95(4), 423-431.

Lazaridis, G., Blanco, J. G., Ratain, M. J., McLeod, H. L., & Innocenti, F. (2014). Integrating pharmacogenomics into the clinical practice of toxicology. Clinical Pharmacology & Therapeutics, 95(3), 258-267.